ESR1 and neoplasm: We found that expression of CXCL1, but not CXCL5, decreased significantly in patients with low TGFBR2 expression (Figure 5A, B), but when we analyzed subtypes of tumor we discovered significant differences only in HER2+, PR + and ER + patients.